Measuring Success and Real-World Outcomes for MASH

Panelists discuss how success in MASH management should be measured through both clinical and economic outcomes. They propose tracking fibrosis regression, hospitalization rates, and patient quality of life as core metrics.

They also explore employer and payer perspectives, focusing on how reduced absenteeism and improved productivity contribute to overall return on investment for liver health programs.

The discussion closes with a call for longitudinal data collection to evaluate interventions’ real-world effectiveness and refine future practice guidelines.